• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay Kits
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • MAPK8 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • MAPK8 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Can DDX3 Inhibitors Lead to the Discovery of Antiviral Therapies?

by Bellbrook Labs / Tuesday, 04 May 2021 / Published in Emerging Targets, HTS Assays
DDX3 inhibitors antiviral therapeutics

DDX3 inhibitors could unlock new treatments for viral diseases. The human immune response is extraordinary and incredibly complex. As the first line of defense against pathogens and foreign DNA, the innate response acts quickly. Viruses activate innate immunity as the host has proteins that recognize viral components. The innate immune response relies on several cell types of proteins such as interferons (INFs) to be effective. This group of cytokines facilitates the removal of viral pathogens. Other types of cytokines include chemokines, interleukins, lymphokines, and tumor necrosis factors (TNF).

While the viral host has cellular proteins that detect, activate, and fight viruses, various proteins allow the virus to thrive and replicate. DEAD-box helicase 3 (DDX3) is an ATP-dependent RNA helicase that can unwind double-stranded nucleic acid, a necessary step in replication, transcription, and translation. Interestingly, it’s also associated with viral entry into the host cell and viral metabolism. As such, DDX3 is essential for the replication and assembly of several viruses, making it an ideal target for potential antiviral therapies. Researchers have found that knocking down DDX3 blocks the replication of several types of viruses.1

Along with the range of viruses that DDX3 could provide relief, scientists believe that DDX3 has potential therapeutic ability towards SARS-CoV-2 (the virus that causes COVID-19). DDX5, which binds to DDX3, has been shown to participate in SARS-CoV replication.2   Furthermore, due to the multifunctional ability, especially in areas of replication, cell adhesion, increased cell migration, and overall enhanced tumor progression functionality, it’s no surprise that DDX3 is also targeted to combat an assortment of cancers.1 DDX3 is increasingly becoming an important antiviral and anticancer therapeutic target.

Finding DDX3 Inhibitors

Researchers have already started discovering hundreds of DDX3 inhibitors; however, there is much to learn as DDX3 plays a role in the activation of the innate immune response in addition to its role in viral replication. The goal would be to decrease or stop viral replication without limiting the positive aspects of DDX3. Targeting specific domains of the multifunctional protein could be the answer.

The Transcreener® ADP² Assay can detect the enzymatic activity of Kinases, ATPases, and any enzyme that produces ADP; consequently, it is ideal for the continued research into DDX3.

The easy-to-use universal ADP assay limits the need for specific reagents. Since DDX3 hydrolyzes ATP forming ADP as a product, measuring the ADP formed can effectively determine DDX3’s ATPase activity with precision. The assay has different formats (fluorescence polarization (FP), time-resolved FRET (TR-FRET), and fluorescence intensity (FI)), enabling a variety of methods as preferred by the researcher.

As we learn more about the role of DDX3, we will continue to add to our growing repertoire of antiviral and anticancer therapies, including DDX3 inhibitors.

Go to DDX3 Assay Page

References

  1. Kukhanova, M. K., Karpenko, I. L., & Ivanov, A. V. (2020). Antiviral and Anticancer Drugs. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070539/
  2. Winnard, P. T., Vesuna, F., & Raman, V. (2021). Targeting host DEAD-box RNA helicase DDX3X for treating viral infections. Antiviral Research, 185(November 2020), 104994. https://doi.org/10.1016/j.antiviral.2020.104994
Tagged under: DDX3, Transcreener ADP ATPase Assay

What you can read next

Lupus NIK Inhibitors
Transcreener ADP Assay Enables Evaluation of NIK Inhibitors in Lupus Drug Discovery
The Major Applications of Kinase Activity Assays
Fighting Infection’s Ghost

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARG in Human Immunity

    Discovering the Emerging Importance of PARG in Immunity

    Poly (ADP-ribose) glycohydrolase (PARG), along ...
  • Helicases Used in Innate Immunity

    Helicases as Powerful Tools in Innate Immunity

    Helicases are among the largest and most highly...
  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP